Different Mid-Term Prognostic Predictors of Major Adverse Events in Diabetic and Nondiabetic Peripheral Artery Disease Presenting With Critical Limb Ischemia
Restricted accessResearch articleFirst published online March, 2016
Different Mid-Term Prognostic Predictors of Major Adverse Events in Diabetic and Nondiabetic Peripheral Artery Disease Presenting With Critical Limb Ischemia
We compared midterm prognostic predictors of peripheral artery disease (PAD) with or without diabetes mellitus (DM) presenting with critical lower limb ischemia (CLI). A total of 172 patients with PAD (109 DM; 63 non-DM) were enrolled. The major adverse events (MAEs) were death or amputation. The diabetic group had a higher MAE rate (39% vs 22%, P = .042) with a mean follow-up duration of 30 ± 19 months. In a multivariate binary logistic regression analysis, revascularization (odds ratio = 0.289, P = .006) and higher serum cholesterol (odds ratio=0.988, P = .027) predicted a lower MAE rate in the DM group. In contrast, the presence of severe chronic kidney disease (stage 4 or 5, odds ratio = 5.238, P = .025) was a positive predictor of MAEs in the nondiabetic group. In conclusion, the prognostic predictors of MAE in diabetic and nondiabetic patients with PAD and CLI were different.
HirschATHaskalZJHertzerNR. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–e654.
2.
MorbachSFurchertHGroblinghoffU. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care. 2012;35(10):2021–2027.
3.
JudeEBOyiboSOChalmersNBoultonAJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24(8):1433–1437.
4.
DormandyJARutherfordRB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1 Pt 2):S1–S296.
5.
LeveyASBoschJPLewisJBGreeneTRogersNRothD. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470.
6.
PatelSSKimmelPLSinghA. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin Nephrol. 2002;22(6):449–458.
7.
. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–S266.
8.
AlnaebMEYoussefFMikhailidisDPHamiltonG. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology. 2006;57(1):65–71.
9.
YoussefFGuptaPSeifalianAMMyintFMikhailidisDPHamiltonG. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology. 2004;55(1):53–62.
10.
MehranRNikolskyE. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int. 2006;69(Suppl 100s):S11–S15.
11.
ApelqvistJElgzyriTLarssonJLondahlMNybergPThorneJ. Factors related to outcome of neuroischemic/ischemic foot ulcer in diabetic patients. J Vasc Surg. 2011;53(6):1582–1588, e1582.
12.
HinchliffeRJAndrosGApelqvistJ. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev. 2012;28(suppl 1):179–217.
13.
OberhuberABeneckeBOrendKHHutschenreiterSMuehlingBM. The diabetic patient has a higher benefit from infrapopliteal revascularization than the non-diabetic patient: a 10-year retrospective study. Diab Vasc Dis Res. 2013;10(1):78–83.
14.
ScaliSTRzucidloEMBjerkeAA. Long-term results of open and endovascular revascularization of superficial femoral artery occlusive disease. J Vasc Surg. 2011;54(3):714–721.
15.
LaveryLAHuntNANdipALaveryDCVan HoutumWBoultonAJ. Impact of chronic kidney disease on survival after amputation in individuals with diabetes. Diabetes Care. 2010;33(11):2365–2369.
16.
SzczechLABestPJCrowleyE. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation. 2002;105(19):2253–2258.
17.
McCulloughPA. Why is chronic kidney disease the 'spoiler' for cardiovascular outcomes?J Am Coll Cardiol. 2003;41(5):725–728.
18.
IribarrenCReedDMChenRYanoKDwyerJH. Low serum cholesterol and mortality. Which is the cause and which is the effect?Circulation. 1995;92(9):2396–2403.
19.
ParaskevasKIWierzbickiASMikhailidisDP. Statins and noncardiac vascular disease. Curr Opin Cardiol. 2012;27(4):392–397.
20.
IribarrenCReedDMBurchfielCMDwyerJH. Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men. JAMA. 1995;273(24):1926–1932.
21.
LiangKWSheuWHLeeWL. Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD40 ligand. Can J Cardiol. 2006;22(8):691–696.
22.
LiangKWLeeWJLeeWLChenYTTingCTSheuWH. Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic syndrome independent of CRP levels. Clin Chim Acta. 2008;388(1-2):41–45.
